- INmune Bio is at the vanguard of reprogramming the innate immune system for the treatment of disease
- The company’s focus is on modulating components of the innate immune system to treat cancer and Alzheimer’s disease
- INmune Bio’s drug candidates include INKmune, INB03 and XPro1595
INmune Bio Inc. (NASDAQ: INMB) is a diversified, clinical-stage biotechnology company headquartered in La Jolla, California. The company is hoping to develop new immunotherapies that reprogram patients’ innate immune systems to allow the immune systems to fight cancer and Alzheimer’s disease. INmune drug candidates INKmune and INB03 may be used to treat cancer, while XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease.
INmune Bio’s vision is to become the leader in reprogramming the innate immune system for the treatment of disease. Innate is an immediate, nonspecific, initial response that serves as a first line of defense against infection and cancer. Most drug-development programs concentrate on the adaptive immune response and ignore innate immunity. INmune Bio harnesses the innate immune system with a targeted biomarker approach.
The company’s INKmune drug is a biologic therapy. INKmune primes NK cells to eliminate minimal residual disease, which is a major cause of cancer relapse and death. NK cells play a vital role in preventing cancer. Later this year, the company expects to begin enrolling patients in a phase I/II trial for women with relapsed refractory ovarian cancer.
INKmune is delivered by simple IV infusion, allowing for the delivery of critical priming signals to patients’ resting NK cells. Once in the system, INKmune encounters resting NK cells. The interaction converts NK cells to primed NK cell (“PiNK”), much like an on-off switch. PiNK then remain primed until they contact and kill cancer cells (http://ibn.fm/zb0GM).
INmune Bio’s INB03 is a protein biologic. The company believes that INB03 could have numerous beneficial effects in patients with cancer. INmune Bio’s initial emphasis is on its ability to inhibit the proliferation and function of myeloid-derived suppressor cells (“MDSC”). By preventing the proliferation and function of MDSC, the company believes that patients will have a stronger immune response to cancer cells.
INmune Bio also believes that INB03 treatment may help patients better respond to other cancer treatments, including immunotherapy. INB03 is a PEGylated protein therapeutic administered as a once-weekly subcutaneous injection, similar to an insulin shot (http://ibn.fm/Dql3j). This summer, the INB03 program will transition into a combination therapy clinical program to prepare for a phase II trial to research patients’ resistance to checkpoint inhibitors because of increased MDSC.
The company’s XPro1595 is a protein biologic that targets soluble TNF (“sTNF”). XPro1595 may trigger many beneficial effects in patients with Alzheimer’s disease by reducing neuroinflammation. XPro1595 targets the microglial immune cells of the brain, which are responsible for neuroinflammation and are activated in many Alzheimer’s disease patients.
INmune Bio continues to develop its product platforms that use a precision therapy approach. The company offers investors the potential for significant ROI as it targets large markets with unmet needs. With its programs in oncology and neurodegenerative disease, INmune Bio is focusing on multiple opportunities that provide sum-of-parts value.
For more information, visit the company’s website at www.INmuneBio.com
NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB